Gastro-retentive, Floating tablet, Central composite design, Repaglinide, Controlled release


Objective: The recent study's objective was to optimize and formulate a controlled-release gastro-retentive floating tablet of RG using a central composite design, which provides continuous release of Repaglinide for up to 24 h.

Methods: Repaglinide gastro-retentive floating tablet (RG-GRF Tablet) was prepared by direct compression method. The optimization was carried out using a three-factor and three-level Central Composite design. The amount of Eudragit RSPO (A), HPMC K-100M (B) and Sodium bicarbonate (C) were selected as independent variables and the Cumulative % drug release in 1.5 h (DR1.5), Cumulative % drug release in 8 h (DR8), Cumulative % drug release in 24 h (DR24) and Floating lag time (FLT) were used as dependent variables.

Results: CCD analysis results shows that predicted and experimental values for optimized formulation were found to be almost similar. Optimized amounts of Eudragit RSPO, HPMC K-100M, and NaHCO3 were 14.351 mg, 44.438 mg, and 10 mg, respectively, with the highest possible desirability value of 0.898. The experimental values at optimized preparation conditions were found to be DR1.5 is 30.68%, DR8 is 64.90%, DR24 is 96.54%, and FLT is 4.41 min. The release data from the optimized formulation were closely matched with the Korsmeyer-Peppas model and in vitro drug release studies indicated that the RG-GRF Tablet continuously releases the drug for 24 h in a controlled manner.

Conclusion: Current research concludes that RG-GRF Tablets provide drug release for up to 24 h, and the derived central composite design can be used for forecasting the DR1.5, DR8 and DR24 as well. RG can also be made more bioavailable by extending the gastric residence time.


Download data is not yet available.


Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics. 2019;11(4). doi: 10.3390/pharmaceutics11040193, PMID 31010054, PMCID PMC6523542.

Sugihara H, Matsui Y, Takeuchi H, Wilding I, Connor A, Abe K. Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies. Eur J Pharm Sci. 2014;53:62-8. doi: 10.1016/j.ejps.2013.11.018, PMID 24316098.

Sahu AK, Verma A. Development and statistical optimization of chitosan and eudragit based gastroretentive controlled release multiparticulate system for bioavailability enhancement of metformin HCl. J Pharm Investig. 2016;46(3):239-52. doi: 10.1007/s40005-016-0229-0.

Vrettos NN, Roberts CJ, Zhu Z. Gastroretentive technologies in tandem with Controlled-release strategies: a potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics. 2021;13(10). doi: 10.3390/pharmaceutics13101591, PMID 34683884, PMCID PMC8539558.

Mali AD, Bathe RS. Development and evaluation of gastroretentive floating tablets of a quinapril HCl by direct compression technique. Int J Pharm Pharm Sci. 2017;9(8):35-46. doi: 10.22159/ijpps.2017v9i8.12463.

Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm. 2016;510(1):144-58. doi: 10.1016/j.ijpharm.2016.05.016. PMID 27173823.

El-Houssieny BM, Wahman L, Arafa NM. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. BioSci Trends. 2010;4(1):17-24. PMID 20305340.

Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625-60. doi: 10.2165/00003495-200161110-00008, PMID 11577798.

Ammar HO. El-feky GS, Ali AMA, Dawood RAG. Enhancement of oral bioavailability of repaglinide by self-nano emulsifying drug delivery system. Int J Pharm Pharm Sci. 2014;6(9):603-6.

Naveen NR, Gopinath C, Rao DS. Design expert supported mathematical optimization of repaglinide gastroretentive floating tablets: in vitro and in vivo evaluation. Future J Pharm Sci. 2017;3(2):140-7. doi: 10.1016/j.fjps.2017.05.003.

Kohli S, Sharma M, Pal A. Ethylcellulose floating microspheres of antidiabetic agent: in vitro and in vivo evaluation. Int J App Pharm. 2016;9(1):44-9. doi: 10.22159/ijap.2017v9i1.16139.

Albetawi S, Abdalhafez A, Abu-Zaid A. A review on recent controlled release strategies for oral drug delivery of repaglinide (a BCS Class II Drug). Pharm Nanotechnol. 2021;9(5):326-38. doi: 10.2174/2211738510666211221165318, PMID 34939558.

Yin LF, Huang SJ, Zhu CL, Zhang SH, Zhang Q, Chen XJ. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev Ind Pharm. 2012;38(11):1371-80. doi: 10.3109/03639045.2011.652635, PMID 22296267.

Sopyan I, Gozali D, Sriwidodo GRK, Guntina RK. Design-expert software (doe): an application tool for optimization in pharmaceutical preparations formulation. Int J App Pharm. 2022;14(4):55-63. doi: 10.22159/ijap.2022v14i4.45144.

He W, Wu M, Huang S, Yin L. Matrix tablets for sustained release of repaglinide: preparation, pharmacokinetics and hypoglycemic activity in beagle dogs. Int J Pharm. 2015;478(1):297-307. doi: 10.1016/j.ijpharm.2014.11.059. PMID 25434592.

Bhikshapathi DVRN, Srinivas I. Preparation and in vivo evaluation of solid dispersions using repaglinide. IJPSDR 2018;10(5). doi: 10.25004/IJPSDR.2018.100502.

Dhole SM, Khedekar PB, Amnerkar ND. Comparison of UV spectrophotometry and high-performance liquid chromatography methods for the determination of repaglinide in tablets. Pharm Methods. 2012;3(2):68-72. doi: 10.4103/2229-4708.103875, PMID 23781481, PMCID PMC3658086.

Naveen NR, Gopinath C, Rao DS. Design expert supported mathematical optimization of repaglinide gastroretentive floating tablets: in vitro and in vivo evaluation. Future J Pharm Sci. 2017;3(2):140-7. doi: 10.1016/j.fjps.2017.05.003.

Barmpalexis P, Kachrimanis K, Malamataris S. Statistical moments in modelling of swelling, erosion and drug release of hydrophilic matrix-tablets. Int J Pharm. 2018;540(1-2):1-10. doi: 10.1016/j.ijpharm.2018.01.052. PMID 29407874.

Charoenying T, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Akkaramongkolporn P, Opanasopit P. Design and optimization of 3D-printed gastroretentive floating devices by central composite design. AAPS PharmSciTech. 2021;22(5):197. doi: 10.1208/s12249-021-02053-3, PMID 34191172.

Pawar MA, Shevalkar GB, Vavia PR. Design and development of gastro-retentive drug delivery system for trazodone hydrochloride: a promising alternative to innovator’s controlled-release tablet. AAPS PharmSciTech. 2022;23(7):251. doi: 10.1208/s12249-022-02404-8, PMID 36071254.

Chambin O, Champion D, Debray C, Rochat Gonthier MH, Le Meste M, Pourcelot Y. Effects of different cellulose derivatives on drug release mechanism studied at a preformulation stage. J Control Release. 2004;95(1):101-8. doi: 10.1016/j.jconrel.2003.11.009. PMID 15013237.

Grund J, Korber M, Bodmeier R. Predictability of drug release from water-insoluble polymeric matrix tablets. Eur J Pharm Biopharm. 2013;85(3 Pt A):650-5. doi: 10.1016/j.ejpb.2013.08.007. PMID 23985775.

Maderuelo C, Zarzuelo A, Lanao JM. Critical factors in the release of drugs from sustained release hydrophilic matrices. J Control Release. 2011;154(1):2-19. doi: 10.1016/j.jconrel.2011.04.002. PMID 21497624.

Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33. doi: 10.1016/s0928-0987(01)00095-1, PMID 11297896.

Homayoonfal M, Khodaiyan F, Mousavi M. Modelling and optimising of physicochemical features of walnut-oil beverage emulsions by the implementation of response surface methodology: effect of preparation conditions on emulsion stability. Food Chem. 2015;174:649-59. doi: 10.1016/j.foodchem.2014.10.117, PMID 25529732.

Myers RH, Montgomery DC, Anderson Cook CM. Response surface methodology: process and product optimization using designed experiments. John Wiley & Sons; 2016.



How to Cite

PATEL, M., & KHAN, M. A. (2023). OPTIMIZATION, DEVELOPMENT AND EVALUATION OF REPAGLINIDE CONTROLLED RELEASE GASTRO-RETENTIVE FLOATING TABLET USING CENTRAL COMPOSITE DESIGN. International Journal of Applied Pharmaceutics, 15(1), 218–226. https://doi.org/10.22159/ijap.2023v15i1.46493



Original Article(s)